Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453219 | 0.97 | ABL1 (0.34) | ABL1RAD52RIN1ADORA2AADORA2B | |
| SCHEMBL19539317 | 0.80 | ADORA2A (0.36) | ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL2058723 | 0.80 | TLR7 (0.46) | — | |
| SCHEMBL20756902 | 0.78 | CDK1 (0.42) | ADORA2AADORA2B | |
| SCHEMBL1146060 | 0.76 | CDK1 (0.43) | ADORA2AADORA2B | |
| SCHEMBL13828436 | 0.75 | XDH (0.36) | ABL1RAD52RIN1PDPK1 | |
| SCHEMBL6897931 | 0.74 | CDK1 (0.46) | ADORA2AADORA2B | |
| SCHEMBL19778471 | 0.73 | LRRK2 (0.34) | ABL1RAD52RIN1PDPK1 | |
| SCHEMBL4160288 | 0.73 | ADORA2A (0.41) | ADORA2AADORA2BMEN1ALDH1A1KMT2A | |
| SCHEMBL30438320 | 0.73 | TUBB4A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262214-A1 | Synthesis of 2-Substituted Adenosines | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1697393-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054269-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262214-A1 | Synthesis of 2-Substituted Adenosines | ADORA3, ADORA1, ADORA2A | ABL1 1012/4885RAD52 3332/4885RIN1 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.